Skip to main content
. Author manuscript; available in PMC: 2018 Oct 1.
Published in final edited form as: Mol Cancer Ther. 2017 Jul 11;16(10):2257–2266. doi: 10.1158/1535-7163.MCT-17-0179

Figure 6. Anti-androgen combinations with cabazitaxel are more effective than similar combinations utilizing docetaxel.

Figure 6

A. TaxR and DU145-DTXR cells were subjected to cell growth assays using either vehicle (DMSO), bicalutamide (10μM), docetaxel (1nM), cabazitaxel (1nM), or a combination of bicalutamide with either docetaxel or cabazitaxel. Cells were counted 72 hours post-treatment. B. TaxR and DU145-DTXR cells were subjected to cell growth assays using either vehicle (DMSO), bicalutamide (10μM), docetaxel (1, 5, or 10nM), or a combination of bicalutamide with either dose of docetaxel. Cells were counted 72 hours post-treatment. C. TaxR and DU145-DTXR cells were subjected to clonogenic assays using either vehicle (DMSO), bicalutamide (10μM), docetaxel (1nM), cabazitaxel (1nM), or a combination of bicalutamide with either docetaxel or cabazitaxel. Colonies were allowed to form for 14 days post-treatment. Colonies were then stained with crystal violet and counted. D. TaxR and DU145-DTXR cells were subjected to cell growth assays using either vehicle (DMSO), enzalutamide (10μM), docetaxel (1nM), cabazitaxel (1nM), or a combination of enzalutamide with either docetaxel or cabazitaxel. Cells were counted 72 hours post-treatment. C = control (DMSO) treatment, Bic = bicalutamide, Enz = enzalutamide, DTX = docetaxel, CTX = cabazitaxel. All data is presented as percent of control mean ± standard deviation. * = p-value ≤ 0.05.